Edurant (rilpivirine)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Edurant (rilpivirine), covering 2011-07-11 to 2021-01-15. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study [Phase 2]